NCT03097068 is a Phase 4 clinical trial of Lucentis in Diabetic Macular Edema, sponsored by Vitreo-Retinal Associates, Michigan.

Who is sponsoring NCT03097068?

NCT03097068 is sponsored by Vitreo-Retinal Associates, Michigan.

What drugs are being tested in NCT03097068?

Interventions in NCT03097068: Lucentis.

What condition does NCT03097068 study?

NCT03097068 studies Diabetic Macular Edema.

Is NCT03097068 still recruiting?

NCT03097068 is currently completed. Last updated 24 October 2022.

Are results published for NCT03097068?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-10-24 · How we verify

NCT03097068

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

Completed Phase 4 Results posted Last updated 24 October 2022

What this trial tests

Phase 4 trial testing Lucentis in Diabetic Macular Edema in 10 participants. Completed in 2 February 2018.

Timeline

19 April 2017

Primary endpoint
6 December 2017

2 February 2018

Quick facts

Lead sponsor	Vitreo-Retinal Associates, Michigan
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	10
Start date	19 April 2017
Primary completion	6 December 2017
Estimated completion	2 February 2018
Sites	1 location across United States

Drugs / interventions tested

Lucentis — full drug profile →

Conditions studied

Diabetic Macular Edema — all drugs for Diabetic Macular Edema →

Sponsor

Vitreo-Retinal Associates, Michigan

Who can join

18 and older, any sex, with Diabetic Macular Edema. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Vascular Endothelial Growth Factor Levels Primary · 12 weeks

An aqueous humor specimen was obtained at baseline and at 12 weeks to determine if the levels of VEGF had decreased with treatment.

Group	Value	95% CI
0.3 mg Lucentis	73.46	40.06 – 112.30

Sponsor's own description

The protocol will measure a number of cytokines in addition to vascular endothelial growth factor in response to 0.3mg Lucentis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lucentis

Trials testing the same drug.

NCT07515079 — Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Diabetic Macular Edema · Phase 3 · recruiting
NCT05439629 — Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration · Phase 3 · completed
NCT05304949 — Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity · completed
NCT05003245 — Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD · Phase 3 · completed
NCT05297292 — A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD · Phase 2, PHASE3 · unknown

Other recruiting trials for Diabetic Macular Edema

Currently open trials in the same condition.

NCT07425522 — A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With D · Phase 1 · recruiting
NCT06984822 — Evaluation of Serum- and OCT Biomarkers in Patients With DME Treated With Anti-VEGF or Dexamethasone Implant · NA · recruiting
NCT07038967 — Non-Center Involving Diabetic Macular Edema Progression in Early Postoperative Period After Phacoemulsification · recruiting
NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
NCT06549023 — Single Session vs Multiple-Session Panretinal Photocoagulation for Treatment of Proliferative Diabetic Retinopathy · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03097068 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vitreo-Retinal Associates, Michigan
Last refreshed: 24 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03097068.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing